Funding of $14 Million Secured by Pahr Therapeutics for Developing Treatments for Pulmonary Arterial Hypertension
Pahr Therapeutics Secures $14 Million Seed Financing for Pulmonary Arterial Hypertension Therapies
Pahr Therapeutics, a biotech company focused on developing novel treatments for pulmonary arterial hypertension (PAH), has recently announced a successful $14 million seed financing round. The funding, led by RA Capital Management, AN Venture Partners, and the University of Tokyo Edge Capital Partners (UTEC), will be used to advance the development of these therapies.
The company, which was founded in the RA Capital incubator, has made significant strides since the seed round. Notable progress includes the appointment of key board members such as Andrew Levin, MD/PhD, Partner at RA Capital, Ken Horne, and Atsushi Usami, PhD. These individuals bring valuable expertise and guidance to Pahr Therapeutics' development efforts.
Pahr Therapeutics is aiming to advance into clinical studies for PAH early in 2026. The company's co-founders, Drs. Yoshikazu Nakaoka, Makoto Okazawa, and Ryotaro Asano, are eager to deploy the seed funding to push their therapeutic candidates through the preclinical and clinical development stages.
Dr. Nakaoka, who directs the Vascular Physiology department at the National Cerebral and Cardiovascular Center (NCVC) in Osaka, expressed his excitement about working with RA Capital Management, AN Venture Partners, and UTEC. He is inspired by the global support for the company and looks forward to translating their scientific platform into clinical candidates for PAH treatment.
Pahr Therapeutics is currently in the early stages after securing this significant seed financing, gearing up to move its novel PAH therapies toward clinical trials in the near future. The focus remains on leveraging this recent funding to make a meaningful impact on the lives of PAH patients.
[1] Pahr Therapeutics Secures $14 Million Seed Financing for Pulmonary Arterial Hypertension Therapies. (2025, August 3). Retrieved from https://www.pahrtherapeutics.com/news/pahr-therapeutics-secures-14-million-seed-financing-for-pulmonary-arterial-hypertension-therapies
[3] Pahr Therapeutics Announces $14 Million Seed Financing Round Led by RA Capital Management, AN Venture Partners, and the University of Tokyo Edge Capital Partners (UTEC). (2025, June 15). Retrieved from https://www.businesswire.com/news/home/20250615005685/en/Pahr-Therapeutics-Announces-14-Million-Seed-Financing-Round-Led-by-RA-Capital-Management-AN-Venture-Partners-and-the-University-of-Tokyo-Edge-Capital-Partners-UTEC
[4] Pahr Therapeutics Secures $14 Million Seed Financing for Pulmonary Arterial Hypertension Therapies. (2025, June 15). Retrieved from https://www.globenewswire.com/news-release/2025/06/15/2290736/0/en/Pahr-Therapeutics-Secures-14-Million-Seed-Financing-for-Pulmonary-Arterial-Hypertension-Therapies.html
[5] Pahr Therapeutics Announces $14 Million Seed Financing Round Led by RA Capital Management, AN Venture Partners, and the University of Tokyo Edge Capital Partners (UTEC). (2025, June 15). Retrieved from https://www.prnewswire.com/news-releases/pahr-therapeutics-announces-14-million-seed-financing-round-led-by-ra-capital-management-an-venture-partners-and-the-university-of-tokyo-edge-capital-partners-utec-301310091.html
- The funds secured by Pahr Therapeutics will not only advance its PAH therapies but also contribute significantly to the medical-conditions and health-and-wellness sector.
- With the successful close of the seed financing round, Pahr Therapeutics is well-positioned to engage in investing opportunities, further strengthening its business and finance strategy.
- As Pahr Therapeutics moves its novel PAH therapies towards clinical trials, it signifies a crucial step in the real-world application of science and technology, demonstrating the potential impact on health-and-wellness and finance industries alike.
